VERTEX PHARMACEUTICALS INC / MA (VRTX) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $429.50M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $157.00M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $329.40M; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $429.50M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $429.50M |
| Deferred revenue · latest quarter (USD) | $157.00M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | $329.40M | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $329.40M |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 7.18B USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 429.50M USD | Accounts Payable, Current |
| Total deferred revenue | 157.00M USD | Contract with Customer, Liability · Deferred Revenue, Current · Deferred Revenue, Noncurrent |
| Deferred revenue due within one year | (m) | Deferred Revenue, Current |
| Deferred revenue due after one year | (m) | Deferred Revenue, Noncurrent · Contract with Customer, Liability · Deferred Revenue, Current |
| Reported other obligations due within one year | 329.40M USD | Other Liabilities, Current |
| Reported other noncurrent obligations | 1.26B USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) | Contract with Customer, Liability · Deferred Revenue, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $329.40M
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Obligation categories | (m) |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $429.50M | $157.00M | $329.40M | (m) | $7.18B | (m) | (m) | (m) | $1.26B | (m) |
| 2026-03-31 | (m) | $489.30M | $218.70M | $407.10M | (m) | $7.12B | (m) | (m) | (m) | $1.26B | (m) |
| 2025-12-31 | (m) | $461.70M | $171.80M | $428.30M | (m) | $6.98B | (m) | (m) | (m) | $1.27B | (m) |
| 2025-09-30 | (m) | $420.30M | $182.00M | $441.50M | (m) | $7.54B | (m) | (m) | (m) | $1.23B | (m) |
| 2025-06-30 | (m) | $442.30M | $146.90M | $425.40M | (m) | $6.86B | (m) | (m) | (m) | $1.20B | (m) |
| 2025-03-31 | (m) | $445.00M | $228.40M | $386.40M | (m) | $6.38B | (m) | (m) | (m) | $951.90M | (m) |
| 2024-12-31 | (m) | $413.00M | $206.80M | $363.00M | (m) | $6.12B | (m) | (m) | (m) | $901.80M | (m) |
| 2024-09-30 | (m) | $395.80M | $220.00M | $357.60M | (m) | $6.61B | (m) | (m) | (m) | $933.30M | (m) |
| 2024-06-30 | (m) | $327.90M | $128.30M | $279.30M | (m) | $5.36B | (m) | (m) | (m) | $876.80M | (m) |
| 2024-03-31 | (m) | $351.40M | $275.80M | $648.60M | (m) | $5.37B | (m) | (m) | (m) | $853.60M | (m) |
| 2023-12-31 | (m) | $364.90M | $170.30M | $527.20M | (m) | $5.15B | (m) | (m) | (m) | $877.70M | (m) |
| 2023-09-30 | (m) | $375.90M | $157.10M | $316.20M | (m) | $5.21B | (m) | (m) | (m) | $869.30M | (m) |
| 2023-06-30 | (m) | $363.00M | $179.10M | $391.00M | (m) | $4.88B | (m) | (m) | (m) | $759.30M | (m) |
| 2023-03-31 | (m) | $323.20M | $236.40M | $377.00M | (m) | $4.54B | (m) | (m) | (m) | $726.50M | (m) |
| 2022-12-31 | (m) | $303.90M | $159.60M | $311.50M | (m) | $4.24B | (m) | (m) | (m) | $685.80M | (m) |
| 2022-09-30 | (m) | $126.90M | $119.50M | $218.00M | (m) | $3.68B | (m) | (m) | (m) | $115.70M | (m) |
| 2022-06-30 | (m) | $198.00M | $134.80M | $238.70M | (m) | $3.65B | (m) | (m) | (m) | $115.40M | (m) |
| 2022-03-31 | (m) | $173.60M | $186.10M | $286.10M | (m) | $3.35B | (m) | (m) | (m) | $117.40M | (m) |
| 2021-12-31 | (m) | $195.00M | $171.70M | $268.40M | (m) | $3.33B | (m) | (m) | (m) | $116.80M | (m) |
| 2021-09-30 | (m) | $127.86M | $104.10M | $201.41M | (m) | $3.09B | (m) | (m) | (m) | $108.47M | (m) |
| 2021-06-30 | (m) | $127.53M | $122.60M | $226.36M | (m) | $3.03B | (m) | (m) | (m) | $107.69M | (m) |
| 2021-03-31 | (m) | $127.84M | $181.20M | $284.17M | (m) | $3.13B | (m) | (m) | (m) | $106.26M | (m) |
| 2020-12-31 | (m) | $155.14M | $191.50M | $317.42M | (m) | $3.06B | (m) | (m) | (m) | $108.36M | (m) |
| 2020-09-30 | (m) | $107.79M | $94.80M | $192.54M | (m) | $3.17B | (m) | (m) | (m) | $428.52M | (m) |
| 2020-06-30 | (m) | $101.45M | $70.70M | $151.78M | (m) | $2.70B | (m) | (m) | (m) | $189.12M | (m) |
| 2020-03-31 | (m) | $100.70M | $76.30M | $179.78M | (m) | $2.43B | (m) | (m) | (m) | $181.75M | (m) |
| 2019-12-31 | (m) | $87.61M | $62.30M | $130.31M | (m) | $2.23B | (m) | (m) | (m) | $183.32M | (m) |
| 2019-09-30 | (m) | $92.53M | $50.20M | $122.58M | (m) | $2.26B | (m) | (m) | (m) | $7.64M | (m) |
| 2019-06-30 | (m) | $77.05M | $60.20M | $113.10M | (m) | $1.96B | (m) | (m) | (m) | $8.01M | (m) |
| 2019-03-31 | (m) | $82.26M | $51.40M | $108.76M | (m) | $1.82B | (m) | (m) | (m) | $6.00M | (m) |
| 2019-01-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $5.38M | (m) |
| 2018-12-31 | (m) | $110.99M | $24.90M | $40.59M | (m) | $1.81B | (m) | (m) | (m) | $26.28M | (m) |
| 2018-09-30 | (m) | $92.15M | $39.77M | $60.36M | (m) | $1.69B | (m) | (m) | (m) | $26.30M | (m) |
| 2018-06-30 | (m) | $83.03M | $32.43M | $59.63M | (m) | $1.62B | (m) | (m) | (m) | $25.59M | (m) |
| 2018-03-31 | (m) | $74.06M | $14.64M | $56.65M | (m) | $1.52B | (m) | (m) | (m) | $27.46M | (m) |
| 2018-01-01 | (m) | (m) | (m) | $36.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $73.99M | $6.89M | $27.03M | $26.05M | $1.50B | (m) | $5.17M | $1.73M | $26.05M | $0.00 |
| 2017-09-30 | (m) | $77.14M | $15.92M | $27.69M | $26.03M | $1.40B | (m) | $13.00M | $2.92M | $26.03M | $0.00 |
| 2017-06-30 | (m) | $75.94M | $11.44M | $24.77M | $25.22M | $1.42B | (m) | $7.28M | $4.16M | $25.22M | $0.00 |
| 2017-03-31 | (m) | $63.15M | $11.80M | $10.95M | $28.47M | $1.26B | (m) | $6.06M | $5.74M | $28.47M | $0.00 |
| 2016-12-31 | (m) | $61.45M | $12.64M | $10.94M | $102.12M | $1.56B | (m) | $6.00M | $6.63M | $102.12M | $0.00 |
| 2016-09-30 | (m) | $50.91M | $15.81M | $51.22M | $30.52M | $1.40B | (m) | $9.25M | $6.56M | $30.52M | $0.00 |
| 2016-06-30 | (m) | $51.30M | $18.88M | $38.22M | $30.65M | $1.38B | (m) | $11.47M | $7.41M | $30.65M | $0.00 |
| 2016-03-31 | (m) | $75.22M | $23.20M | $18.12M | $31.82M | $1.37B | (m) | $14.71M | $8.49M | $31.82M | $0.00 |
| 2015-12-31 | (m) | $74.94M | $26.01M | $14.37M | $31.78M | $1.41B | (m) | $16.30M | $9.71M | $31.78M | $0.00 |
| 2015-09-30 | (m) | $78.90M | $31.50M | $9.53M | $34.99M | $1.36B | (m) | $14.00M | $17.50M | $34.99M | $0.00 |
| 2015-06-30 | (m) | $72.70M | $35.95M | $13.20M | $41.25M | $1.33B | (m) | $14.93M | $21.02M | $41.25M | $0.00 |
| 2015-03-31 | (m) | $43.52M | $39.92M | $4.68M | $32.70M | $1.17B | (m) | $15.92M | $24.00M | $32.70M | $0.00 |
| 2014-12-31 | (m) | $71.19M | $45.28M | $4.80M | $21.71M | $1.24B | (m) | $17.47M | $27.81M | $21.71M | $0.00 |
| 2014-09-30 | (m) | $38.47M | $55.93M | $11.71M | $15.95M | $1.25B | (m) | $21.21M | $34.72M | $15.95M | $0.00 |
| 2014-06-30 | (m) | $55.36M | $65.28M | $14.44M | $15.67M | $945.55M | (m) | $27.17M | $38.10M | $15.67M | $0.00 |
| 2014-03-31 | (m) | $49.57M | $72.72M | $32.47M | $12.03M | $966.23M | (m) | $28.84M | $43.89M | $12.03M | $0.00 |
| 2013-12-31 | (m) | $49.33M | $70.97M | $24.74M | $11.59M | $962.64M | (m) | $21.51M | $49.46M | $11.59M | $0.00 |
| 2013-09-30 | (m) | $51.53M | $108.36M | $21.82M | $10.78M | $1.10B | (m) | $31.01M | $77.35M | $10.78M | $0.00 |
| 2013-06-30 | (m) | $48.57M | $116.97M | $23.62M | $16.05M | $1.04B | (m) | $32.90M | $84.07M | $16.05M | $0.00 |
| 2013-03-31 | (m) | $59.63M | $125.83M | $25.20M | $16.68M | $1.42B | (m) | $35.53M | $90.30M | $16.68M | $0.00 |
| 2012-12-31 | (m) | $101.29M | $123.81M | $19.70M | $13.90M | $1.52B | (m) | $27.57M | $96.24M | $13.90M | $0.00 |
| 2012-09-30 | (m) | $83.73M | $130.93M | $13.94M | $28.74M | $1.45B | (m) | $27.30M | $103.63M | $28.74M | $0.00 |
| 2012-06-30 | (m) | $59.35M | $137.37M | $13.35M | $28.01M | $1.36B | (m) | $27.30M | $110.07M | $28.01M | $0.00 |
| 2012-03-31 | (m) | $73.23M | $146.68M | (m) | $10.88M | $1.24B | (m) | $30.49M | $116.19M | $10.88M | $0.00 |
| 2011-12-31 | (m) | $74.64M | $163.13M | (m) | $7.29M | $1.24B | (m) | $45.04M | $118.09M | $7.29M | $0.00 |
| 2011-09-30 | (m) | $49.25M | $181.92M | (m) | $7.85M | $1.36B | (m) | $55.70M | $126.22M | $7.85M | $0.00 |
| 2011-06-30 | (m) | $67.28M | $199.05M | (m) | $6.23M | $1.31B | (m) | $65.02M | $134.04M | $6.23M | $0.00 |
| 2011-03-31 | (m) | $34.88M | $218.61M | $2.00M | (m) | $1.15B | (m) | $74.19M | $144.42M | (m) | $0.00 |
| 2010-12-31 | (m) | $35.85M | $234.67M | $6.15M | (m) | $1.22B | (m) | $74.62M | $160.05M | (m) | $0.00 |
| 2010-09-30 | (m) | $24.64M | $276.94M | $8.69M | (m) | $1.24B | (m) | $98.98M | $177.96M | (m) | $0.00 |
| 2010-06-30 | (m) | $46.49M | $273.50M | $9.00M | (m) | $827.07M | (m) | $78.27M | $195.22M | (m) | $0.00 |
| 2010-03-31 | (m) | $29.12M | $285.06M | $14.28M | (m) | $779.69M | (m) | $69.58M | $215.49M | (m) | $0.00 |
| 2009-12-31 | (m) | $36.99M | $300.53M | $15.23M | (m) | $859.14M | (m) | $74.96M | $225.57M | (m) | $0.00 |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |